A decade ago, India’s bioeconomy was valued at $10 billion. Today it stands at $165 billion. The question is no longer whether India can compete globally in biotechnology—it is whether the country can build the institutional architecture to lead it.
India’s transformation into a serious biotech contender has unfolded with a speed that has surprised even its most optimistic advocates. The bioeconomy has expanded 16-fold between 2014 and 2024, contributing approximately 4.25 per cent of GDP and placing India alongside the United States and China in terms of bio-based economic share.
The 2025 India Bioeconomy Report confirms a compound annual growth rate of 17.9 per cent over the past four years, with bioindustrial and biopharma segments together accounting for over 80 per cent of total value. The enterprise base has expanded with equal vigour—from 5,365 businesses in 2021 to 10,075 by 2024, a near-doubling in three years driven by collaborative programmes, research funding, and a policy environment increasingly willing to treat biotechnology as national infrastructure rather than niche industrial policy.
Government as Ecosystem Architect, Not Mere Grant-Giver
The most consequential shift in India’s biotech story is not a single breakthrough product or a record-setting funding round—it is the reorientation of government’s role from passive funder to active ecosystem architect. The BioE3 Policy—Biotechnology for Economy, Environment, and Employment—represents this pivot with unusual clarity, setting a bioeconomy target of $300 billion by 2030 and $1 trillion by 2047 whilst treating biotechnology as core national infrastructure. India’s Gross Expenditure on Research and Development has more than doubled over the past decade, rising from ₹60,196 crore in 2013–14 to ₹1,27,381 crore in 2024, providing the scientific foundation upon which sector-specific missions are being constructed.
The World Bank-backed National Biopharma Mission exemplifies this orchestration at scale. Designed to accelerate India’s transition from generic drug manufacturing to advanced biopharmaceutical creation, the NBM provides funding, mentorship, and shared infrastructure to thousands of startups and SMEs—enabling indigenous vaccine development, biosimilar programmes, cell-based therapies, and affordable medical devices that would otherwise remain beyond the reach of smaller enterprises.
The Serum Institute of India’s position commanding roughly 24 per cent of global vaccine supply by 2024 is the most visible product of decades of precisely this kind of coordinated partnership between research institutions, manufacturers, and regulatory bodies. India’s early achievement of 20 per cent ethanol blending in petrol by 2025—five years ahead of the original schedule—demonstrates the same collaborative logic applied to the bioindustrial segment, with sugar mills, biofuel companies, agricultural research institutions, and government ministries operating as a coherent, aligned system rather than parallel bureaucracies.
The Innovation Frontier: Where India Must Now Compete
Consolidating existing strengths in generics, vaccines, and biofuels is necessary but insufficient. The global cell and gene therapy market, estimated at $20 billion and expanding rapidly, represents the frontier that will define which nations genuinely lead biotechnology over the next two decades rather than merely participating in it. India currently lacks the specialised translational centres, sophisticated regulatory capacity, and depth of clinical- industrial collaboration that this segment demands.
Building those capabilities requires a deliberate architectural response—BioE3’s vision of regional bio-innovation districts, where universities, national laboratories, hospitals, and industrial units co-locate and share both physical infrastructure and knowledge networks, points toward the right model. Shared biopharma facilities and incubators under the NBM already demonstrate how the “commons” approach lowers entry barriers and compresses the journey from proof-of-concept to clinical trial.
India’s formidable strengths in information technology and data science represent an underutilised advantage in this frontier race. Integrating electronic health records, genomic datasets, and AI-driven drug discovery models—within robust data governance frameworks—could position India as a global exporter of computational biology and digital health platforms, not merely a manufacturer of their outputs. The bioinformatics infrastructure that this would require is, in many respects, more achievable for India than the capital-intensive laboratory buildout that gene therapy manufacturing demands.
Deepening Collaboration to Cement Global Hub Status
Sustaining the current trajectory requires moving from opportunistic collaboration to genuinely mission-driven co-creation. Long-term, outcome-oriented programmes focused on grand challenges where India possesses both need and capability—antimicrobial resistance, neglected tropical diseases, climate-resilient crops, low-cost primary care diagnostics—must be co-designed by scientific agencies, industry consortia, and relevant ministries, with stable multi-year funding and clear metrics: products approved, lives reached, carbon emissions reduced. Regulatory frameworks must evolve in parallel, as gene editing, AI-driven discovery, and population-scale genomics raise complex questions of safety, privacy, and equity that cannot be resolved by scientific agencies alone.
The international dimension matters equally. World Bank co-design of missions, alignment of development finance with domestic policy reform, and embedded performance accountability have already demonstrated their value within the NBM. Deepening those global partnerships—whilst anchoring regional strengths in Telangana’s biopharma clusters,
Maharashtra’s bio industrial manufacturing, and Karnataka’s agri-biotech ecosystem. That will determine whether India emerges as a true global hub or remains a large and capable participant in a race others are leading. The infrastructure, the talent, and the policy intent are already present. What India now requires is the institutional discipline to act, consistently and collectively, as co-creators rather than competitors.